Results 181 to 190 of about 10,402 (207)

Trabectedin Plus Pegylated Liposomal Doxorubicin in Recurrent Ovarian Cancer

Journal of Clinical Oncology, 2010
PurposeThe objective of this study was to compare the efficacy and safety of trabectedin plus pegylated liposomal doxorubicin (PLD) with that of PLD alone in women with recurrent ovarian cancer after failure of first-line, platinum-based chemotherapy.Patients and MethodsWomen ≥ 18 years, stratified by performance status (0 to 1 v 2) and platinum ...
Lisyanskaya, AS, Krasner, CN, Kaye, SB, Herzog, TJ, Monk, BJ, Poveda, AM, Lebedinsky, CA, Park, YC, Nam, JH, Vergote, IB, Ngan, HYS, Shen, K, Bidzinski, M, Ghatage, P, Gorbounova, VA, Rolski, J, Makhson, AN, PujadeLauraine, E, Muggia, FM, Vermorken, JB   +19 more
openaire   +4 more sources

Pegylated liposomal doxorubicin (Caelyx™) in recurrent ovarian cancer

Cancer Treatment Reviews, 2002
Epithelial ovarian cancer (EOC) is the most common gynaecological malignancy in the Western world and a leading cause of death. Patients with relapsed EOC are incurable and therefore the toxicity of palliative chemotherapy and effects on health-related Quality of Life are important factors.
J, Stebbing, A, Gaya
openaire   +2 more sources

Pegylated Liposomal Doxorubicin

Drugs, 2008
Pegylated liposomal doxorubicin (Doxil, Caelyx) is associated with less frequent neutropenia, alopecia and cardiotoxicity than conventional doxorubicin and has an improved pharmacokinetic profile, allowing for intravenous administration over 1 hour. In the US and EU (as well as a number of other countries), pegylated liposomal doxorubicin is approved ...
openaire   +2 more sources

Pegylated liposomal doxorubicin in the treatment of cancers of the breast and ovary

Expert Opinion on Pharmacotherapy, 2006
Peglyated liposomal doxorubicin was developed to maintain or enhance the demonstrated antineoplastic effects of doxorubicin, while improving the toxicity profile associated with this important cytotoxic agent. Accumulating clinical data have confirmed the activity of pegylated liposomal doxorubicin in cancers of the breast and ovary. Furthermore, Phase
openaire   +2 more sources

Doxorubicin liposomal, Doxorubicin pegylated liposomal

2010
Ines Mader, Patrizia Fürst-Weger, Robert Mader, Elisabeth Nogler-Semenitz, Sabine Wassertheurer   +4 more
openaire   +1 more source

Reduced cardiotoxicity and comparable efficacy in a phase IIItrial of pegylated liposomal doxorubicin HCl(CAELYX™/Doxil®) versus conventional doxorubicin forfirst-line treatment of metastatic breast cancer

Annals of Oncology, 2004
M E R O'Brien, M Inbar, Armando Santoro   +2 more
exaly  

An integrated assessment of PEGylated liposomal doxorubicin products

Journal of Controlled Release, 2016
openaire   +2 more sources

Unbedenklichkeitsaspekte bei der Anwendung von pegyliertem liposomalem Doxorubicin bei Krebspatienten

Drugs, 2012
David S Alberts, David S Alberts, Alberts David S   +2 more
exaly  

Radiation recall dermatitis induced by pegylated liposomal doxorubicin

Anti-Cancer Drugs, 2003
Antonio, Jimeno, Eva M, Ciruelos, Daniel, Castellano, Begoña, Caballero, Jose Luis, Rodriguez-Peralto, Hernán, Cortés-Funes   +5 more
openaire   +2 more sources

Phase II study of pegylated liposomal doxorubicin (Caelyx®) and docetaxel as first-line treatment in metastatic breast cancer

Annals of Oncology, 2004
A Alexopoulos, A Ardavanis, G Rigatos
exaly